Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024
23 avr. 2024 02h15 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024 Publication of Annual Report 2023...
Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024
23 avr. 2024 02h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024 Publication of Annual Report 2023...
Sequana Medical announces Annual General Meeting of Shareholders on 25 May 2023
23 avr. 2024 01h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION23 April 2024, 07:00 am CET Publication of Annual Report 2023 Ghent, Belgium – 23 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or...
Transparency Notifications from Shareholders
11 avr. 2024 12h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION 11 April 2024, 06:00 pm CEST Ghent, Belgium – 11 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in...
Transparency Notifications from Shareholders
08 avr. 2024 12h30 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION 8 April 2024, 06:30 pm CEST Ghent, Belgium – 8 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the...
Transparency Notifications from Shareholders
03 avr. 2024 12h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION3 April 2024, 06:00 pm CEST Ghent, Belgium – 3 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the...
Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure
03 avr. 2024 01h00 HE
|
Sequana Medical NV
Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance Ghent, Belgium – 3 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana...
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
28 mars 2024 03h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CET alfapump® – PMA1 submitted to US FDA and accepted for substantive review, extensive feedback just received from...
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
26 mars 2024 02h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION26 March 2024, 07:00 a.m. CET Ghent, Belgium, 26 March 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the...
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
25 mars 2024 02h00 HE
|
Sequana Medical NV
MOJAVE – US Phase 1/2a study of DSR 2.0 for treatment of heart failure Previously reported strong data maintained after three-months follow-up: Diuretic response remained nearly normalized, with a...